Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2004

Open Access 01-12-2004 | Research

A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay

Authors: Walter J Miller, Mark L Kayton, Angela Patton, Sarah O'Connor, Mei He, Huan Vu, Galina Baibakov, Dominique Lorang, Vladimir Knezevic, Elise Kohn, H Richard Alexander, David Stirling, Faribourz Payvandi, George W Muller, Steven K Libutti

Published in: Journal of Translational Medicine | Issue 1/2004

Login to get access

Abstract

Reliable quantitative evaluation of molecular pathways is critical for both drug discovery and treatment monitoring. We have modified the CAM assay to quantitatively measure vascular density, endothelial proliferation, and changes in protein expression in response to anti-angiogenic and pro-angiogenic agents. This improved CAM assay can correlate changes in vascular density with changes seen on a molecular level. We expect that these described modifications will result in a single in vivo assay system, which will improve the ability to investigate molecular mechanisms underlying the angiogenic response.
Appendix
Available only for authorised users
Literature
1.
Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in-vivo by dominant-negative Flk-1mutant. Nature. 1994, 367: 576-579. 10.1038/367576a0.CrossRefPubMed
2.
Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in-vivo. Nature. 1993, 362: 841-844. 10.1038/362841a0.CrossRefPubMed
3.
Gasparini G, Harris AL: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol. 1995, 13: 765-782.PubMed
4.
Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A Randomized trial of bevacizumab, an antivascular endothelial growth factor antibody for metastatic renal cancer. N Engl J Med. 2003, 349: 427-434. 10.1056/NEJMoa021491.PubMedCentralCrossRefPubMed
5.
Giantonio BJ, Levy D, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson B: Bevacizumab (anti-VEGF) plus IFL irinotecan, fluorouracil. leucovorin) as front line therapy for advanced colorectal cancer (advCRC): Results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. ASCO. 2003, 1024:
6.
Toi M: Endothelial growth factors: Target of antiangiogenesis, Ovarian Cancer Research notebook. The Cancer Journal. 2003, 8: 1-7.
7.
Auerbach W, Auerbach R: Angiogenesis inhibition: a review. Pharmacol Ther. 1994, 63: 265-311. 10.1016/0163-7258(94)90027-2.CrossRefPubMed
8.
Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N: Angiogenesis assays: a critical overview. Clin Chem. 2003, 49: 32-40. 10.1373/49.1.32.CrossRefPubMed
9.
Ribatti D, Vacca A, Roncali L, Dammacco F: The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis. Curr Pharm Biotechnol. 2000, 1: 73-82.CrossRefPubMed
10.
Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature. 1990, 348: 555-557. 10.1038/348555a0.CrossRefPubMed
11.
Yasukawa T, Kimura H, Tabata Y, Miyamoto H, Honda Y, Ikada Y, Ogura Y: Targeted delivery of anti-angiogenic agent TNP-470 using water-soluble polymer in the treatment of choroidal neovascularization. Invest Ophthalmol Vis Sci. 1999, 40: 2690-2696.PubMed
12.
Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO: Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. Proc Natl Acad Sci. 2000, 6: 6427-6432. 10.1073/pnas.97.12.6427.CrossRef
13.
Wang J, Lou P, Henkin J: Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem. 2000, 77: 465-73. 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D.CrossRefPubMed
14.
Catalano A, Romano M, Robuffo I, Strizzi L, Procopio A: Methionine aminopeptidase-2 regulates human mesothelioma cell survival: Role of Bcl-2 expression and telomerase activity. Am J Path. 2001, 159: 721-731.PubMedCentralCrossRefPubMed
15.
Brooks PC, Montgomery AM, Cheresh DA: Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol Biol. 1999, 129: 257-69. 10.1385/1-59259-249-X:257.PubMed
16.
Zhang LH: Novel potent class of small molecules, inhibitors of tubulin polymerization and TNF-a production with anti-tumor activity. Proc Amer Assoc Cancer Res. 2003, 44: LB-22-2
17.
Englert CR, Baibakov GV, Emmert-Buck MR: Layered expression scanning: rapid molecular profiling of tumor samples. Cancer Res. 2000, 60: 1526-1530.PubMed
18.
Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR: Post-analysis follow-up and validation of microarray experiments. Nature Genet. 2002, 32: 509-514. 10.1038/ng1034.CrossRefPubMed
19.
Suzuki E, Nishimatsu H, Nagata D, Satonaka H, Goto A, Omata M, Fujita T, Nagai R, Hirata Y: Constitutive activation of proto-oncogen protein p21 induces cell cycle arrest in the G1 phase in contact-inhibited vascular endothelial cells. Hypertens Res. 2002, 25: 773-778. 10.1291/hypres.25.773.CrossRefPubMed
20.
Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, Biemann K, Liu JO: Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol. 1997, 4: 461-471. 10.1016/S1074-5521(97)90198-8.CrossRefPubMed
21.
Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM: The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci. 1997, 94: 6099-6103. 10.1073/pnas.94.12.6099.PubMedCentralCrossRefPubMed
Metadata
Title
A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay
Authors
Walter J Miller
Mark L Kayton
Angela Patton
Sarah O'Connor
Mei He
Huan Vu
Galina Baibakov
Dominique Lorang
Vladimir Knezevic
Elise Kohn
H Richard Alexander
David Stirling
Faribourz Payvandi
George W Muller
Steven K Libutti
Publication date
01-12-2004
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2004
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-2-4

Other articles of this Issue 1/2004

Journal of Translational Medicine 1/2004 Go to the issue

Review

Antiangiogenic gene therapy of cancer: recent developments

Research

Clinical significance of BRAF mutations in metastatic melanoma

Commentary

Conflicts of interest in translational research

Research

The effect of chemotherapy combined with recombination mutant human tumor necrosis factor on advanced cancer

Methodology

A modified human ELISPOT assay to detect specific responses to primary tumor cell targets

Review

Translation research: from accurate diagnosis to appropriate treatment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits